

## Product portfolio

Our offering comprises **best-in-class PCR assays** for targeted resequencing of all human canonical exons of protein coding genes (both Sanger and massively parallel sequencing)

### WGS/WES variant confirmation



1 million PCR assays, of which over 10,000 have been validated for variant confirmation

### Sample ID panel



An optimized 50-SNP multiplex panel capable of identifying your samples in a single PCR reaction

### Targeted resequencing



54 validated gene panels totalling up to 223 genes and 4008 assays

### NGS gap filling




Extend your preferred enrichment method with our assays to fill low coverage regions

All our assays have been thoroughly validated *in silico*, resulting in an off-the-shelf PCR success rate of >97%. The optimized design parameters allow uniform PCR conditions while ensuring uniform sequencing coverage.

- ✓ Avoid SNPs in primer annealing sites
- ✓ Minimize secondary structures
- ✓ Maximize assay specificity
- ✓ Optimize GC content, annealing temperature and other parameters

## From variant to confirmation in one week

Save time and money on logistics, administration, assay design and variant validation by using pxlence PCR assays. By means of our state-of-the-art pipeline, **our products can be customized to fit every need.**





## Contact

URL : [www.pxlence.com](http://www.pxlence.com)  
 email : [info@pxlence.com](mailto:info@pxlence.com)

LinkedIn : [www.linkedin.com/company/pxlence](http://www.linkedin.com/company/pxlence)  
 Twitter : [www.twitter.com/pxlence](http://www.twitter.com/pxlence)

## Superior assay quality

To showcase the quality of our assays, we've tested a random set of 2300. Sequencing results show that almost **95% of the assays generate less than 2% aspecific sequencing coverage**. This correlates very well with the *in silico* specificity score depicted on our website, allowing you to critically assess the quality of each of our assays. More details about the assay quality characteristics can be found in our Biomolecular Detection and Quantification paper (*PubMed ID 27077044*).



## Some of our customers



Dr. Hans Atli Dahl  
CEO of Amplexa Genetics, Odense, Denmark

*At Amplexa Genetics we have been using pxlence assays for some time now and we are very satisfied with the solution. It is saving us valuable time at no extra cost. Prior to pxlence we spent a lot of time on designing primers and subsequent testing and optimizing the amplicons. Now we just order the pre-designed and ready to use amplicons from pxlence and run them at the defined standard conditions – works every time. Adds no extra cost but saves us a lot of time!*

## References

Our assays have been used in the development of a wide range of NGS gene panels, both for research and diagnostic purposes. In addition, our customers use the assays for Sanger based validation of variants.

[Targeted resequencing and variant validation using pxlence PCR assays](#)  
2294 assays - *PubMed ID 27077044*

[Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis](#)  
16 genes - 375 assays - *PubMed ID 22261762*

[Molecular diagnostics for congenital hearing loss including 15 deafness genes using a next generation sequencing platform](#)  
16 genes - 376 assays - *PubMed ID 24612714*

[Flexible, scalable, and efficient targeted resequencing on a benchtop sequencer for variant detection in clinical practice](#)  
265 genes - over 4000 assays - *PubMed ID 25504618*

More papers using our assays are available on our website.